Dr. Craig Devoe, MD
Hematology & Oncology (Hematology & Oncology Physician)
The Monter Cancer Center, 450 Lakeville Road
Lake Success, NY 11042
- Medicare participating
At a glance
- Medical school
- State University of New York at Stony Brook, School of Medicine (1994)
- Years since graduation
- 32
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 276
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1994Medical school: State University of New York at Stony Brook, School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
NY license 201557
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- North Shore University Hospital Manhasset, NY
- Long Island Jewish Medical Center New Hyde PArk, NY
- Northwell Hospital Glen Cove Glen Cove, NY
Medical groups
- North Shore Health System Medical Faculty Group Practice Inc (164 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 276
- Services billed
- 1,708
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 551 | 170 |
| Established patient office or other outpatient visit, 40-54 minutes | 144 | 88 |
| Established patient office or other outpatient visit, 20-29 minutes | 94 | 76 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 53 | 46 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 46 | 28 |
| New patient office or other outpatient visit, 60-74 minutes | 45 | 45 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 24 | 19 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Lake Success, NY | 35 |
| Ondansetron Odt (ondansetron) Other prescribers in Lake Success, NY | 33 |
| Lonsurf (trifluridine/tipiracil hcl) | 30 |
| Furosemide Other prescribers in Lake Success, NY | 26 |
| Dexamethasone Other prescribers in Lake Success, NY | 22 |
| Imatinib Mesylate | 17 |
| Eliquis (apixaban) Other prescribers in Lake Success, NY | 16 |
| Metoclopramide Hcl Other prescribers in Lake Success, NY | 15 |
| Gleevec (imatinib mesylate) | 14 |
| Spironolactone Other prescribers in Lake Success, NY | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $53.45 in total to this clinician.
| Genentech, Inc. | $53.45 |
|---|
| Education | $53.45 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genentech, Inc. Sep 29, 2025 | Education in-kind | $53.45 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $119,953 in research payments for these studies, mostly to the institutions running them.
- A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06190951 - Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM)
Immunocore Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.